Advanced Breast Cancer
Conditions
Brief summary
This study is a multicentre, open label, non-randomized phase I study. The main objectives of the study are to determine the pharmacokinetic profile of the drug at different dose levels in the patients with Advanced Breast Cancer. Maximum Tolerated Dose (MTD) and safety of Paclitaxel Nanoparticle will also be simultaneously assessed.
Interventions
DRUGNanoxel (Paclitaxel Nanoparticle formulation )
Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
Sponsors
Fresenius Kabi Oncology Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female patients with histopathologically /cytologically confirmed advanced breast cancer, refractory / recurrent\* to previous anthracycline treatment as adjuvant or first line therapy for metastasis. * Patients with ER/PR -ve or ER/PR receptor status unknown (defined as no histopathological evidence for confirmation of ER/PR status) * Patients must be of 18-65 years of age (inclusive of both) * Patients with ECOG performance status between 0 - 2 * Patients with at least one measurable lesion as per RECIST
Exclusion criteria
* Patients with ER/PR positive status. Patients who demonstrate HER2 over expression will be excluded. Alternatively, the patients enrolled should have previously received trastuzumab. HER2 over expression should be demonstrated by IHC 3+, IHC 2+ or with FISH/CIS. * Patients with known history of hypersensitivity to paclitaxel or any other taxane or compounds chemically / biologically related to paclitaxel or excipients. * Patients requiring any concurrent chemotherapy, hormonal therapy immunotherapy, therapy with biologicals or radiotherapy for the disease. (Patients requiring local radiotherapy for non- target bone lesion will be included). * Patients with known CNS lesions (brain metastasis or carcinomatous meningitis).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes of the study would be the Pharmacokinetic data at all the four dose levels (220, 260, 310 and 375 mg/m2); Ability to identify a dose higher than 220 mg/m2 that demonstrate better efficacy and manageable toxicity | Throughout the study |
Secondary
| Measure | Time frame |
|---|---|
| evaluation of the effect of Paclitaxel Nanoparticle formulation on QTc. | Throughout the study |
Countries
India
Contacts
Primary ContactShivakant Mishra, PhD
Backup ContactAmit Sharma, MD
Outcome results
None listed